公开(公告)号：US20060211646A1

公开(公告)日：2006-09-21

申请号：US11366243

申请日：2006-03-02

申请人： Laura Ferro ,  Massimo Lacobelli ,  Paul Richardson

发明人： Laura Ferro ,  Massimo Lacobelli ,  Paul Richardson

IPC分类号： A61K48/00 ,  A61K31/66 ,  A61K31/337

CPC分类号： A61K31/711 ,  A61K31/17 ,  A61K31/195 ,  A61K31/337 ,  A61K31/665 ,  A61K31/7088 ,  A61K45/06 ,  A61K2300/00

摘要： The use of defibrotide as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described.

摘要翻译： 描述了使用defibrotide作为抗肿瘤剂，单独或与具有抗肿瘤作用的其它活性成分组合。

公开(公告)号：US5605891A

公开(公告)日：1997-02-25

申请号：US94626

申请日：1993-07-21

申请人： Giuseppe Prino ,  Ennio Lanzarotti ,  Benito Casu ,  Laura Ferro

发明人： Giuseppe Prino ,  Ennio Lanzarotti ,  Benito Casu ,  Laura Ferro

IPC分类号： A61K31/715 ,  A61K31/15 ,  A61P9/10 ,  A61P25/02 ,  C08B37/08 ,  C08B37/10 ,  A61K31/725

CPC分类号： A61K31/15

摘要： Polysaccharides and more in particular glycosaminoglycans, their mixtures, fractions and derivatives thereof are effective agents in the therapy of acute peripheral neuropathies of traumatic and ischemic origin and in the therapy of acute peripheral neuropathies of toxic origin.

摘要翻译： 多糖和更特别是糖胺聚糖，其混合物，级分和衍生物是治疗创伤性和缺血性起源的急性外周神经病和治疗有毒起源的急性周围神经病的有效试剂。

公开(公告)号：US5731302A

公开(公告)日：1998-03-24

申请号：US722720

申请日：1996-09-30

申请人： Giancarlo Farolfi ,  Franco Lattuada ,  Laura Ferro

发明人： Giancarlo Farolfi ,  Franco Lattuada ,  Laura Ferro

IPC分类号： A61K9/107 ,  A61K9/00 ,  A61K9/12 ,  A61K31/60 ,  A61K47/38 ,  A61P1/00 ,  A61K31/615

CPC分类号： A61K31/606 ,  A61K9/0014 ,  A61K9/0031 ,  A61K47/38

摘要： The invention discloses new compositions of mesalazine in the form of aqueous suspensions, characterized in that they are more stable than those of the prior art. The compositions contain colloidal cellulose and one or more hydrophilic thickening agents.

摘要翻译： 本发明公开了以水性悬浮液形式的美沙拉嗪的新组合物，其特征在于它们比现有技术更稳定。 组合物含有胶体纤维素和一种或多种亲水增稠剂。

公开(公告)号：US07338777B2

公开(公告)日：2008-03-04

申请号：US10868798

申请日：2004-06-17

申请人： Roberto Porta ,  Franco Cattaneo ,  Laura Ferro

发明人： Roberto Porta ,  Franco Cattaneo ,  Laura Ferro

IPC分类号： C12Q1/37

CPC分类号： C12Q1/37 ,  C12Q1/56 ,  G01N2333/968

摘要： Method for determining the biological activity of defibrotide by a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.

摘要翻译： 用于通过以下方法确定去纤维蛋白的生物学活性：a）使抗纤维蛋白溶酶，纤溶酶和纤溶酶特异性的底物接触，其通过与纤溶酶反应提供可测量的产物; 和b）测量连续形成的产物的量，从而确定去纤维蛋白酶的生物活性。

公开(公告)号：US5676965A

公开(公告)日：1997-10-14

申请号：US505148

申请日：1995-07-21

申请人： Laura Ferro ,  Ennio Lanzarotti

发明人： Laura Ferro ,  Ennio Lanzarotti

IPC分类号： C07H21/04 ,  A61F2/00 ,  A61K20060101 ,  A61K9/08 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/70 ,  A61K35/12 ,  A61K35/38 ,  A61P3/08 ,  A61P3/10 ,  A61P25/02 ,  C07H21/00

CPC分类号： A61K31/711 ,  Y10S514/866

摘要： A pharmaceutical composition comprising a polydeoxyribonucleotide of random sequence formula is disclosed, and P.sub.v, (dAp).sub.w, (dGp).sub.x, (dTp).sub.y, (dCp).sub.z wherein P.sub.v is 1-5 phosphoric radicals, (dAp).sub.w is 12-24 deoxyadenylic monomers, (dGp).sub.x is 10-20 deoxyguanylic monomers, (dTp).sub.y is 13-26 deoxythymidylic monomers, and (dCp).sub.z is 10-20 deoxycytidylic monomers; wherein the polydeoxyribonucleotide has: a homogenous anodic mobility in electrophoresis, an extinction coefficient E.sup.1%.sub.1 cm at 260.+-.1 nm=220.+-.10, an extinction coefficient E.sub.230 /E.sub.260 =0.45.+-.0.04, a molar extinction coefficient (referred to phosphorous), .epsilon.(P)=7750.+-.500, a rotary power �.alpha.!.sup.20.degree..sub.D =53.degree..+-.6, and a reversible hyperchromicity as percent in native DNA h=15.+-.5, in combination with a pharmaceutically acceptable carrier or diluent. A method of treating or preventing a diabetic neuropathy using the polydeoxyribonucleotide is also shown.

摘要翻译： 公开了包含随机序列式的多脱氧核糖核苷酸的药物组合物，Pv中的（dAp）w，（dGp）x，（dTp）y，（dCp）z在Pv中为1-5个磷酸基，（dAp）w为12-24 脱氧腺苷单体（dGp）x为10-20脱氧鸟苷基单体，（dTp）y为13-26脱氧胸苷单体，（dCp）z为10-20脱氧胞苷单体; 其中所述多脱氧核糖核苷酸具有：电泳中均匀的阳极迁移率，260 +/- 1nm处的消光系数E1％1cm = 220 +/- 10，消光系数E230 / E260 = 0.45 +/- 0.04，摩尔消光系数 （称为磷），ε（P）= 7750 +/- 500，旋转功率α20°D = 53°+/- 6，以及天然DNA中百分比的可逆增色h = 15 +/- 5 ，与药学上可接受的载体或稀释剂组合。 还显示了使用多脱氧核糖核苷酸治疗或预防糖尿病性神经病变的方法。

公开(公告)号：US08771663B2

公开(公告)日：2014-07-08

申请号：US12755321

申请日：2010-04-06

申请人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

发明人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

IPC分类号： A61K38/19

CPC分类号： A61K31/7088 ,  A61K31/711 ,  A61K38/18 ,  A61K38/193 ,  A61K38/2053 ,  A61K31/70 ,  A61K2300/00

摘要： The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

摘要翻译： 本发明涉及能够增加哺乳动物的外周血中循环中的干细胞和祖细胞的量的新型制剂; 该制剂的特征在于其含有脱铁肽与至少一种具有动员造血祖细胞，优选G-CSF的能力的造血因子组合。 在一个实施方案中，制剂包含两种可单独施用的制剂，一种含有能够动员造血祖细胞的造血因子，另一种含有脱铁肽。 该制剂有效地实现造血祖细胞的数量增加，其大于由造血因子单独实现的造血祖细胞数量的增加。

公开(公告)号：US20100298413A1

公开(公告)日：2010-11-25

申请号：US12596005

申请日：2008-03-25

申请人： Laura Ferro ,  Massimo Iacobelli ,  Cinara Echart

发明人： Laura Ferro ,  Massimo Iacobelli ,  Cinara Echart

IPC分类号： A61K31/711 ,  A61P13/00 ,  A61P13/12

CPC分类号： A61K31/7088 ,  A61K31/711

摘要： The present study has demonstrated that heparanase expression and activity was increased in human microvascular endothelial cells and rat kidney epithelial cells growing under hyperglycemia condition, as found in diabetic nephropathy disease. Oligotide was able to: —downregulate the heparanase gene expression; —downregulate the cell surface protein expression; —decrease the heparanase enzymatic activity. Since heparanase is a critical factor in maintaining glomerular basement membrane integrity and is elevated in renal diseases, as for instance diabetic nephropathies. Oligotide should be considered for the management of these diseases.

摘要翻译： 本研究已经证明，在糖尿病肾病中发现，在高血糖状态下生长的人微血管内皮细胞和大鼠肾上皮细胞中肝素酶的表达和活性增加。 寡肽能够：下调肝素酶基因表达; 下调细胞表面蛋白表达; - 降低肝素酶的酶活性。 由于乙酰肝素酶是维持肾小球基底膜完整性的关键因素，并且在肾脏疾病中升高，例如糖尿病性肾病。 应该考虑使用寡核苷酸来治疗这些疾病。

公开(公告)号：US20100254938A1

公开(公告)日：2010-10-07

申请号：US12755321

申请日：2010-04-06

申请人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

发明人： Laura Ferro ,  Roberto Porta ,  Massimo Iacobelli ,  Massimo Alessandro Gianni ,  Carmelo Carlo Stella

IPC分类号： A61K38/19 ,  A61P7/00

CPC分类号： A61K31/7088 ,  A61K31/711 ,  A61K38/18 ,  A61K38/193 ,  A61K38/2053 ,  A61K31/70 ,  A61K2300/00

摘要： The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterised in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilise haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

摘要翻译： 本发明涉及能够增加哺乳动物的外周血中循环中的干细胞和祖细胞的量的新型制剂; 该制剂的特征在于其含有脱铁肽与至少一种具有动员造血祖细胞，优选G-CSF的能力的造血因子组合。 在一个实施方案中，制剂包含两种可单独施用的制剂，一种含有能够动员造血祖细胞的造血因子，另一种含有脱铁肽。 该制剂有效地实现造血祖细胞的数量增加，其大于由造血因子单独实现的造血祖细胞数量的增加。

公开(公告)号：US20060148745A1

公开(公告)日：2006-07-06

申请号：US11236197

申请日：2005-09-27

申请人： Manlio Palumbo ,  Barbara Gatto ,  Rodolfo Pescador ,  Roberto Porta ,  Laura Ferro

发明人： Manlio Palumbo ,  Barbara Gatto ,  Rodolfo Pescador ,  Roberto Porta ,  Laura Ferro

IPC分类号： A61K48/00 ,  C07H21/04

CPC分类号： C12N15/115 ,  A61K38/00 ,  C12N2310/16 ,  C12N2310/343

摘要： The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.

摘要翻译： 本研究旨在鉴定以高水平选择性为特征的组织蛋白酶G的非肽抑制剂，并且可有效地用于治疗和预防炎性发生和促凝血状态。 根据本发明的组织蛋白酶G抑制适体由具有至少60个核苷酸的链长并且基本上不经历有效碱基配对的线性DNA或多核苷酸序列组成。

公开(公告)号：US20050009131A1

公开(公告)日：2005-01-13

申请号：US10868798

申请日：2004-06-17

申请人： Roberto Porta ,  Franco Cattaneo ,  Laura Ferro

发明人： Roberto Porta ,  Franco Cattaneo ,  Laura Ferro

IPC分类号： C12Q1/37 ,  C12Q1/56 ,  C12Q1/68 ,  G01N33/48

CPC分类号： C12Q1/37 ,  C12Q1/56 ,  G01N2333/968

摘要： An enzymatic method for determining the biological activity of defibrotide is described. This method, which is based on the capacity of defibrotide to potentiate the enzymatic activity of plasmin, comprises the steps of: a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product and b) measuring the amount of product formed at successive times.

摘要翻译： 描述了用于测定去纤维蛋白酶的生物活性的酶法。 该方法基于抗纤维蛋白酶增强纤溶酶的酶活性的能力，包括以下步骤：a）使脱纤维素，纤溶酶和纤溶酶特异性的底物接触，其通过与纤溶酶反应提供可测量的 产品和b）测量连续形成的产品的量。